RGEN vs BRKR vs WAT vs AZTA vs A

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus 2. 1% for Bruker Corporation (BRKR). Agilent Technologies, Inc. (A) offers the better valuation at 26. 0x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Agilent Technologies, Inc.

(A) is the cheapest at 26. 0x versus Repligen Corporation at 147. 0x. On forward P/E, Agilent Technologies, Inc. is actually cheaper at 19. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 35x versus Waters Corporation's 4. 70x — a reasonable growth-adjusted valuation.

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.

3%, compared to -81. 0% for Azenta, Inc. (AZTA). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus BRKR's +67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.

07β versus Azenta, Inc. 's 2. 17β — meaning AZTA is approximately 103% more volatile than WAT relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 81% for Bruker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus 2. 1% for Bruker Corporation (BRKR). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waters Corporation (WAT) is the more profitable company, earning 20.

3% net margin versus -9. 4% for Azenta, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus -1. 9% for AZTA. At the gross margin level — before operating expenses — WAT leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 35x versus Waters Corporation's 4. 70x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Agilent Technologies, Inc. (A) trades at 19. 9x forward P/E versus 64. 3x for Repligen Corporation — 44. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 140. 5% to $44. 67.

In this comparison, A (0.

8% yield), BRKR (0. 3% yield) pay a dividend. RGEN, WAT, AZTA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Agilent Technologies, Inc.

(A) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23), 0. 8% yield, +205. 7% 10Y return). Azenta, Inc. (AZTA) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (A: +205. 7%, AZTA: +123. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RGEN is a small-cap high-growth stock; BRKR is a small-cap quality compounder stock; WAT is a mid-cap quality compounder stock; AZTA is a small-cap quality compounder stock; A is a mid-cap quality compounder stock. A pays a dividend while RGEN, BRKR, WAT, AZTA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.